Increased tyrosine hydroxylase expression accompanied by glial changes within the non-lesioned hemisphere in the 6-hydroxydopamine model of Parkinson's disease

Restorative Neurology and Neuroscience

Volumn 32, Issue 4, 2014, Pages 447-462

  Schlachetzki, Johannes C M ^a   Marxreiter, Franz ^a   Regensburger, Martin ^a,b   Kulinich, Anna ^a,c   Winner, Beate ^b   Winkler, Jurgen ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Dnipropetrovsk State Medical Academy   (Ukraine)

Author keywords

6 hydroxydopamine; astrocyte; axonal degeneration; microglia; oligodendrocyte; Parkinson's disease

Indexed keywords

INTERLEUKIN 1BETA; OXIDOPAMINE; PROTEIN S100B; TYROSINE 3 MONOOXYGENASE; ACTIN BINDING PROTEIN; ADRENERGIC RECEPTOR STIMULATING AGENT; AIF1 PROTEIN, RAT; CALCIUM BINDING PROTEIN; DOPAMINE TRANSPORTER; GLIAL FIBRILLARY ACIDIC PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; ASTROCYTOSIS; BRAIN DAMAGE; CONTROLLED STUDY; CORPUS STRIATUM; GENE EXPRESSION; GLIA CELL; GLIOSIS; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LESION STRIATUM; MALE; MEDIAL FOREBRAIN BUNDLE; MICROGLIA; NON LESION STRIATUM; NONHUMAN; OLIGODENDROGLIA; OPTICAL DENSITY; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; UPREGULATION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GLIA; HEMISPHERIC DOMINANCE; METABOLISM; NERVE FIBER; PATHOLOGY; SUBSTANTIA NIGRA PARS COMPACTA; TIME; WISTAR RAT;

ADRENERGIC AGENTS; ANIMALS; CALCIUM-BINDING PROTEINS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FUNCTIONAL LATERALITY; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; MALE; MICROFILAMENT PROTEINS; NERVE FIBERS; NEUROGLIA; OXIDOPAMINE; PARKINSON DISEASE; PARS COMPACTA; RATS; RATS, WISTAR; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 84922380951     PISSN: 09226028     EISSN: 18783627     Source Type: Journal    
DOI: 10.3233/RNN-130371     Document Type: Article

References (83)

1. Afonso-Oramas, D., Cruz-Muros, I., Barroso-Chinea, P., Alvarez de la Rosa, D., Castro-Hernandez, J., Salas-Hernandez, J., Giraldez, T., Gonzalez-Hernandez, T. (2010). The dopamine transporter is differentially regulated after dopaminergic lesion. Neurobiol Dis, 40(3), 518-530.
2. Aguzzi, A., Barres, B.A. & Bennett, M.L. (2013). Microglia: Scapegoat. saboteur, or something else? Science, 339(6116), 156-161.
3. Banati, R.B., Daniel, S.E. & Blunt, S.B. (1998). Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinsons disease. Mov Disord, 13(2), 221-227.
4. Beraud, D., Hathaway, H.A., Trecki, J., Chasovskikh, S., Johnson, D.A., Johnson, J.A., Federoff, H.J., Shimoji, M., Mhyre, T.R. & Maguire-Zeiss, K.A. (2013). Microglial activation and antioxidant responses induced by the Parkinsons disease protein alpha-synuclein. J Neuroimmune Pharmacol, 8(1), 94-117.
5. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K. & Seitelberger, F. (1973). Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci, 20(4), 415-455.
6. Blanchard, V., Anglade, P., Dziewczapolski, G., Savasta, M., Agid, Y. & Raisman-Vozari, R. (1996). Dopaminergic sprouting in the rat striatum after partial lesion of the substantia nigra. Brain Res, 709(2), 319-325.
7. Bove, J., Prou, D., Perier, C. & Przedborski, S. (2005).Toxin-induced models of Parkinsons disease. NeuroRx, 2(3), 484-494.
8. Buffo, A., Rite, I., Tripathi, P., Lepier, A., Colak, D., Horn, A.P., Mori, T. & Gotz, M. (2008). Origin and progeny of reactive gliosis: A source of multipotent cells in the injured brain. Proc Natl Acad Sci U S A, 105(9), 3581-3586.
9. Cao, S., Standaert, D.G. & Harms, A.S. (2012). The gamma chain subunit of Fc receptors is required for alpha-synuclein-induced pro-inflammatory signaling in microglia. J Neuroinflammation, 9(1), 259.
10. Cheng, H.C., Ulane, C.M. & Burke, R.E. (2010). Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol, 67(6), 715-725.
11. Cho, B.P., Sugama, S., Shin, D.H., DeGiorgio, L.A., Kim, S.S., Kim, Y.S., Lim, S.Y., Park, K.C., Volpe, B.T., Cho, S. & Joh, T.H. (2003). Microglial phagocytosis of dopamine neurons at early phases of apoptosis. Cell Mol Neurobiol, 23(4-5), 551-560.
12. Chung, C.Y., Koprich, J.B., Siddiqi, H. & Isacson, O. (2009). Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci, 29(11), 3365-3373.
13. Cohen, A.D., Tillerson, J.L., Smith, A.D., Schallert, T. & Zigmond, M.J. (2003). Neuroprotective effects of prior limb use in 6-hydroxydopamine-Treated rats: Possible role of GDNF. J Neurochem, 85(2), 299-305.
14. Dauer, W. & Przedborski, S. (2003). Parkinsons disease: Mechanisms and models. Neuron, 39(6), 889-909.
15. de Jong, E.K., Dijkstra, I.M., Hensens, M., Brouwer, N., van Amerongen, M., Liem, R.S., Boddeke, H.W. & Biber, K. (2005). Vesicle-mediated transport and release of CCL21 in endangered neurons: A possible explanation for microglia activation remote from a primary lesion. J Neurosci, 25(33), 7548-7557.
16. de la Fuente-Fernandez, R., Schulzer, M., Kuramoto, L., Cragg, J., Ramachandiran, N., Au, W.L., Mak, E., McKenzie, J., McCormick, S., Sossi, V., Ruth, T.J., Lee, C.S., Calne, D.B. & Stoessl, A.J. (2011). Age-specific progression of nigrostriatal dysfunction in Parkinsons disease. Ann Neurol, 69(5), 803-810.
17. Decressac, M., Mattsson, B. & Bjorklund, A. (2012). Comparison of the behavioural and histological characteristics of the 6-OHDA and alpha-synuclein rat models of Parkinsons disease. Exp Neurol, 235(1), 306-315.
18. Deloulme, J.C., Raponi, E., Gentil, B.J., Bertacchi, N., Marks, A., Labourdette, G. & Baudier, J. (2004). Nuclear expression of S100B in oligodendrocyte progenitor cells correlates with differentiation toward the oligodendroglial lineage and modulates oligodendrocytes maturation. Mol Cell Neurosci, 27(4), 453-465.
19. Dervan, A.G., Meshul, C.K., Beales, M., McBean, G.J., Moore, C., Totterdell, S., Snyder, A.K. & Meredith, G.E. (2004). Astroglial plasticity and glutamate function in a chronic mouse model of Parkinsons disease. Exp Neurol, 190(1), 145-156.
20. Deumens, R., Blokland, A. & Prickaerts, J. (2002). Modeling Parkinsons disease in rats: An evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol, 175(2), 303-317.
21. Fahn, S. (2003). Description of Parkinsons disease as a clinical syndrome. Ann N Y Acad Sci, 991, 1-14.
22. Fang, C., Yin, J., Xu, Z., Wang, Y., Xu, H., Zhou, H. & Gao, C. (2011). Striatal dopaminergic fiber recovery after acute LDOPA treatment in 6-hydroxydopamine (6-OHDA) lesioned rats. Cell Biochem Biophys, 59(1), 49-56.
23. Fearnley, J.M. & Lees, A.J. (1991). Ageing and Parkinsons disease: Substantia nigra regional selectivity. Brain, 114(Pt 5), 2283-2301.
24. Fellner, L., Irschick, R., Schanda, K., Reindl, M., Klimaschewski, L., Poewe, W., Wenning, G.K. & Stefanova, N. (2013). Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia, 61(3), 349-360.
25. Gerecke, K.M., Jiao, Y., Pagala, V. & Smeyne, R.J. (2012). Exercise does not protect against MPTP-induced neurotoxicity in BDNF haploinsufficient mice. PLoS One, 7(8), e43250.
26. Gordon, M.N., Schreier, W.A., Ou, X., Holcomb, L.A. & Morgan, D.G. (1997). Exaggerated astrocyte reactivity after nigrostriatal deafferentation in the aged rat. J Comp Neurol, 388(1), 106-119.
27. Goss, J.R. & Morgan, D.G. (1995). Enhanced glial fibrillary acidic protein RNA response to fornix transection in aged mice. J Neurochem, 64(3), 1351-1360.
28. Grealish, S., Xie, L., Kelly, M. & Dowd, E. (2008). Unilateral axonal or terminal injection of 6-hydroxydopamine causes rapid-onset nigrostriatal degeneration and contralateral motor impairments in the rat. Brain Res Bull, 77(5), 312-319.
29. Gundersen, H.J., Bendtsen, T.F., Korbo, L., Marcussen, N., Moller, A., Nielsen, K., Nyengaard, J.R., Pakkenberg, B., Sorensen, F.B., Vesterby, A., & et al. (1988). Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS, 96(5), 379-394.
30. Hachem, S., Aguirre, A., Vives, V., Marks, A., Gallo, V. & Legraverend, C. (2005). Spatial and temporal expression of S100B in cells of oligodendrocyte lineage. Glia 51(2), 81-97.
31. Halliday, G.M. & Stevens, C.H. (2011). Glia: Initiators and progressors of pathology in Parkinsons disease. Mov Disord, 26(1), 6-17.
32. Henning, J., Strauss, U., Wree, A., Gimsa, J., Rolfs, A., Benecke, R. & Gimsa, U. (2008). Differential astroglial activation in 6-hydroxydopamine models of Parkinsons disease. Neurosci Res, 62(4), 246-253.
33. Henry, V., Paille, V., Lelan, F., Brachet, P. & Damier, P. (2009). Kinetics of microglial activation and degeneration of dopaminecontaining neurons in a rat model of Parkinson disease induced by 6-hydroxydopamine. J Neuropathol Exp Neurol, 68(10), 1092-1102.
34. Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M. & Hashizume, Y. (2003). Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinsons disease brains. Acta Neuropathol, 106(6), 518-526.
35. Ishida, Y., Nagai, A., Kobayashi, S. & Kim, S.U. (2006). Upregulation of protease-Activated receptor-1 in astrocytes in Parkinson disease: Astrocyte-mediated neuroprotection through increased levels of glutathione peroxidase. J Neuropathol Exp Neurol, 65(1), 66-77.
36. Jonsson, G. (1980). Chemical neurotoxins as denervation tools in neurobiology. Annu Rev Neurosci, 3, 169-187.
37. Kettenmann, H., Kirchhoff, F. & Verkhratsky, A. (2013). Microglia: New roles for the synaptic stripper. Neuron, 77(1), 10-18.
38. Kim, W.G., Mohney, R.P., Wilson, B., Jeohn, G.H., Liu, B. & Hong, J.S. (2000). Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: Role of microglia. J Neurosci, 20(16), 6309-6316.
39. Kirik, D., Rosenblad, C. & Bjorklund, A. (1998). Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol, 152(2), 259-277.
40. Klegeris, A., Pelech, S., Giasson, B.I., Maguire, J., Zhang, H., McGeer, E.G. & McGeer, P.L. (2008). Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol Aging, 29(5), 739-752.
41. Kurkowska-Jastrzebska, I., Wronska, A., Kohutnicka, M., Czlonkowski, A. & Czlonkowska, A. (1999). MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinsons disease. Acta Neurobiol Exp (Wars), 59(1), 1-8.
42. Langston, J.W., Forno, L.S., Tetrud, J., Reeves, A.G., Kaplan, J.A. & Karluk, D. (1999). Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1, 2, 3, 6-Tetrahydropyridine exposure. Ann Neurol, 46(4), 598-605.
43. Lawson, L.J., Perry, V.H., Dri, P. & Gordon, S. (1990). Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience, 39(1), 151-170.
44. Lee, C.S., Samii, A., Sossi, V., Ruth, T.J., Schulzer, M., Holden, J.E., Wudel, J., Pal, P.K., de la Fuente-Fernandez, R., Calne, D.B. & Stoessl, A.J. (2000). In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinsons disease. Ann Neurol, 47(4), 493-503.
45. Leme, R.J. & Chadi, G. (2001). Distant microglial and astroglial activation secondary to experimental spinal cord lesion. Arq Neuropsiquiatr, 59(3-A), 483-492.
46. Lessner, G., Schmitt, O., Haas, S.J., Mikkat, S., Kreutzer, M., Wree, A. & Glocker, M.O. (2010). Differential proteome of the striatum from hemiparkinsonian rats displays vivid structural remodeling processes. J Proteome Res, 9(9), 4671-4687.
47. Lieu, C.A. & Subramanian, T. (2012). The interhemispheric connections of the striatum: Implications for Parkinsons disease and drug-induced dyskinesias. Brain Res Bull, 87(1), 1-9.
48. Ma, S.Y., Roytta, M., Rinne, J.O., Collan, Y. & Rinne, U.K. (1997). Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinsons disease using disector counts. J Neurol Sci, 151(1), 83-87.
49. Maeda, T., Nagata, K. & Yoshida, Y. (2008). Exogenous l-DOPA induce no dopamine immuno-reactivity in striatal astroglias and microglias of adult rats with extensive nigro-striatal dopaminergic denervation. Neurosci Lett, 433(3), 255-258.
50. Marinova-Mutafchieva, L., Sadeghian, M., Broom, L., Davis, J.B., Medhurst, A.D. & Dexter, D.T. (2009). Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: A time course study in a 6-hydroxydopamine model of Parkinsons disease. J Neurochem, 110(3), 966-975.
51. McGeer, P.L., Itagaki, S., Boyes, B.E. & McGeer, E.G. (1988). Reactive microglia are positive forHLA-DRin the substantia nigra of Parkinsons and Alzheimers disease brains. Neurology, 38(8), 1285-1291.
52. McGeer, P.L. & McGeer, E.G. (2008). Glial reactions in Parkinsons disease. Mov Disord, 23(4), 474-483.
53. McGeer, P.L., Schwab, C., Parent, A. & Doudet, D. (2003). Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1, 2, 3, 6-Tetrahydropyridine administration. Ann Neurol, 54(5), 599-604.
54. Mirza, B., Hadberg, H., Thomsen, P. & Moos, T. (2000). The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinsons disease. Neuroscience, 95(2), 425-432.
55. Mladenovic, A., Perovic, M., Raicevic, N., Kanazir, S., Rakic, L. & Ruzdijic, S. (2004). 6-Hydroxydopamine increases the level of TNFalpha and baxmRNAin the striatum and induces apoptosis of dopaminergic neurons in hemiparkinsonian rats. Brain Res, 996(2), 237-245.
56. Mogi, M., Harada, M., Kondo, T., Riederer, P. & Nagatsu, T. (1995). Brain beta 2-microglobulin levels are elevated in the striatum in Parkinsons disease. J Neural Transm Park Dis Dement Sect, 9(1), 87-92.
57. Nimmerjahn, A., Kirchhoff, F. & Helmchen, F. (2005). Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science, 308(5726), 1314-1318.
58. ODell, S.J., Gross, N.B., Fricks, A.N., Casiano, B.D., Nguyen, T.B. & Marshall, J.F. (2007). Running wheel exercise enhances recovery from nigrostriatal dopamine injury without inducing neuroprotection. Neuroscience, 144(3), 1141-1151.
59. Pasinetti, G.M., Hassler, M., Stone, D. & Finch, C.E. (1999). Glial gene expression during aging in rat striatum and in long-Term responses to 6-OHDA lesions. Synapse, 31(4), 278-284.
60. Petzinger, G.M., Walsh, J.P., Akopian, G., Hogg, E., Abernathy, A., Arevalo, P., Turnquist, P., Vuckovic, M., Fisher, B.E., Togasaki, D.M. & Jakowec, M.W. (2007). Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1, 2, 3, 6-Tetrahydropyridine-lesioned mouse model of basal ganglia injury. J Neurosci, 27(20), 5291-5300.
61. Reynolds, A.D., Glanzer, J.G., Kadiu, I., Ricardo-Dukelow, M., Chaudhuri, A., Ciborowski, P., Cerny, R., Gelman, B., Thomas, M.P., Mosley, R.L. & Gendelman, H.E. (2008). Nitrated alpha-synuclein-Activated microglial profiling for Parkinsons disease. J Neurochem, 104(6), 1504-1525.
62. Riederer, P. & Wuketich, S. (1976). Time course of nigrostriatal degeneration in parkinsons disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm, 38(3-4), 277-301.
63. Rojanathammanee, L., Murphy, E.J. & Combs, C.K. (2011). Expression of mutant alpha-synuclein modulates microglial phenotype in vitro. J Neuroinflammation, 8, 44.
64. Saavedra, A., Baltazar, G., Santos, P., Carvalho, C.M. & Duarte, E.P. (2006). Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: Role of neuron-glia crosstalk. Neurobiol Dis, 23(3), 533-542.
65. Saijo, K., Crotti, A. & Glass, C.K. (2010). Nuclear receptors, inflammation, and neurodegenerative diseases. Adv Immunol, 106, 21-59.
66. Sarre, S., Yuan, H., Jonkers, N., Van Hemelrijck, A., Ebinger, G. & Michotte, Y. (2004). In vivo characterization of somatodendritic dopamine release in the substantia nigra of 6-hydroxydopamine-lesioned rats. J Neurochem, 90(1), 29-39.
67. Sathe, K., Maetzler, W., Lang, J.D., Mounsey, R.B., Fleckenstein, C., Martin, H.L., Schulte, C., Mustafa, S., Synofzik, M., Vukovic, Z., Itohara, S., Berg, D. & Teismann, P. (2012). S100B is increased in Parkinsons disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-Alpha pathway. Brain, 135(Pt 11), 3336-3347.
68. Scherfler, C., Donnemiller, E., Schocke, M., Dierkes, K., Decristoforo, C., Oberladstatter, M., Kolbitsch, C., Zschiegner, F., Riccabona, G., Poewe, W. & Wenning, G. (2002). Evaluation of striatal dopamine transporter function in rats by in vivo beta-[123I]CIT pinhole SPECT. Neuroimage, 17(1), 128-141.
69. Seifert, G., Schilling, K. & Steinhauser, C. (2006). Astrocyte dysfunction in neurological disorders: A molecular perspective. Nat Rev Neurosci, 7(3), 194-206.
70. Sheng, J.G., Shirabe, S., Nishiyama, N. & Schwartz, J.P. (1993). Alterations in striatal glial fibrillary acidic protein expression in response to 6-hydroxydopamine-induced denervation. Exp Brain Res, 95(3), 450-456.
71. Sidoryk-Wegrzynowicz, M., Wegrzynowicz, M., Lee, E., Bowman, A.B. & Aschner, M. (2011). Role of astrocytes in brain function and disease. Toxicol Pathol, 39(1), 115-123.
72. Smith, B.A., Goldberg, N.R. & Meshul, C.K. (2011). Effects of treadmill exercise on behavioral recovery and neural changes in the substantia nigra and striatum of the 1-methyl-4-phenyl-1, 2, 3, 6-Tetrahydropyridine-lesioned mouse. Brain Res, 1386, 70-80.
73. Song, Y.J., Halliday, G.M., Holton, J.L., Lashley, T., OSullivan, S.S., McCann, H., Lees, A.J., Ozawa, T., Williams, D.R., Lockhart, P.J. & Revesz, T.R. (2009). Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. J Neuropathol Exp Neurol, 68(10), 1073-1083.
74. Stromberg, I., Bjorklund, H., Dahl, D., Jonsson, G., Sundstrom, E. & Olson, L. (1986). Astrocyte responses to dopaminergic denervations by 6-hydroxydopamine and 1-methyl-4-phenyl-1, 2, 3, 6-Tetrahydropyridine as evidenced by glial fibrillary acidic protein immunohistochemistry. Brain Res Bull, 17(2), 225-236.
75. Tajiri, N., Yasuhara, T., Shingo, T., Kondo, A., Yuan, W., Kadota, T., Wang, F., Baba, T., Tayra, J.T., Morimoto, T., Jing, M., Kikuchi, Y., Kuramoto, S., Agari, T., Miyoshi, Y., Fujino, H., Obata, F., Takeda, I., Furuta, T. & Date, I. (2010). Exercise exerts neuroprotective effects on Parkinsons disease model of rats. Brain Res, 1310, 200-207.
76. Takagi, S., Hayakawa, N., Kimoto, H., Kato, H. & Araki, T. (2007). Damage to oligodendrocytes in the striatum after MPTP neurotoxicity in mice. J Neural Transm, 114(12), 1553-1557.
77. Theodore, S., Cao, S., McLean, P.J. & Standaert, D.G. (2008). Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol, 67(12), 1149-1158.
78. Torres, E.M., Lane, E.L., Heuer, A., Smith, G.A., Murphy, E. & Dunnett, S.B. (2011). Increased efficacy of the 6-hydroxydopamine lesion of the median forebrain bundle in small rats, by modification of the stereotaxic coordinates. J Neurosci Methods, 200(1), 29-35.
79. Ulusoy, A., Decressac, M., Kirik, D. & Bjorklund, A. (2010). Viral vector-mediated overexpression of alpha-synuclein as a progressive model of Parkinsons disease. Prog Brain Res, 184, 89-111.
80. Vives, V., Alonso, G., Solal, A.C., Joubert, D. & Legraverend, C. (2003). Visualization of S100B-positive neurons and glia in the central nervous system of EGFP transgenic mice. J Comp Neurol, 457(4), 404-419.
81. Wang, L., Magen, I., Yuan, P.Q., Subramaniam, S.R., Richter, F., Chesselet, M.F. & Tache, Y. (2012). Mice overexpressing wild-Type human alpha-synuclein display alterations in colonic myenteric ganglia and defecation. Neurogastroenterol Motil, 24(9), e425-e436.
82. Yuan, H., Sarre, S., Ebinger, G. & Michotte, Y. (2005). Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal6-OHDAlesions as rat models of Parkinsons disease. J Neurosci Methods, 144(1), 35-45.
83. Zhang, W., Wang, T., Pei, Z., Miller, D.S., Wu, X., Block, M.L., Wilson, B., Zhou, Y., Hong, J.S. & Zhang, J. (2005). Aggregated alpha-synuclein activates microglia: A process leading to disease progression in Parkinsons disease. FASEB J, 19(6), 533-542.